These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 28954755)
41. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis. Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696 [TBL] [Abstract][Full Text] [Related]
42. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923 [No Abstract] [Full Text] [Related]
43. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod. Feige J; Schernthaner C; Wipfler P; Sellner J Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857 [TBL] [Abstract][Full Text] [Related]
44. Warts and all: Fingolimod and unusual HPV-associated lesions. Triplett J; Kermode AG; Corbett A; Reddel SW Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266 [TBL] [Abstract][Full Text] [Related]
45. Early and recurrent macular oedema in a patient treated with fingolimod. Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961 [No Abstract] [Full Text] [Related]
49. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients. Hovi A; Airas L J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874 [No Abstract] [Full Text] [Related]
50. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis. Datt J; Baldock L; Pull E; Webber B Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942 [TBL] [Abstract][Full Text] [Related]
51. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod? Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536 [TBL] [Abstract][Full Text] [Related]
52. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice]. Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440 [TBL] [Abstract][Full Text] [Related]
53. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. Saida T; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Ueda K; Auberson LZ; Tsumiyama I; Nagato K; Kira JI BMC Neurol; 2017 Jan; 17(1):17. PubMed ID: 28129749 [TBL] [Abstract][Full Text] [Related]
54. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336 [TBL] [Abstract][Full Text] [Related]
55. The autonomic balance predicts cardiac responses after the first dose of fingolimod. Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812 [TBL] [Abstract][Full Text] [Related]
58. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594 [TBL] [Abstract][Full Text] [Related]
59. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study. Tichá V; Kodým R; Počíková Z; Kadlecová P Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735 [TBL] [Abstract][Full Text] [Related]
60. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal. Cellerino M; Bonavita S; Ferrero M; Inglese M; Boffa G J Neurol Sci; 2020 Nov; 418():117156. PubMed ID: 33010653 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]